Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 2 S, 2011, Pages 35-42

  Arévalo Herrera, Myriam ^a,b   Soto, Liliana ^a,b   Perlaza, Blanca Liliana ^a,b   Céspedes, Nora ^a,b   Vera, Omaira ^a,b   Lenis, Ana Milena ^a,b   Bonelo, Anilza ^a,b   Corradin, Giampietro ^c   Herrera, Sócrates ^a,b  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b Malaria Vaccine and Drug Development Center   (Colombia)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; N PEPTIDE; R PEPTIDE; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; MALARIA VACCINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HEPATOMA CELL; HUMAN; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM VIVAX MALARIA; SPOROZOITE; VACCINATION; ADOLESCENT; BLOOD; IMMUNOLOGY; PHYSIOLOGY; PLASMODIUM VIVAX;

PLASMODIUM VIVAX;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; VACCINATION; YOUNG ADULT;

EID: 79952470466     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.09-0507     Document Type: Article

References (52)

1. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106. (Pubitemid 32552576)
2. Clyde DF, 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ 68 (Suppl): 9- 12.
3. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R, 1991. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45: 539-547.
4. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164. (Pubitemid 34297774)
5. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS, 1984. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 132: 909-913. (Pubitemid 14189116)
6. Herrera S, Corradin G, Are´valo-Herrera M, 2007. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23: 122-128. (Pubitemid 46274505)
7. Sharma S, Pathak S, 2008. Malaria vaccine: a current perspective. J Vector Borne Dis 45: 1-20. (Pubitemid 351345753)
8. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS, 1999. Preerythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41: 397-402. (Pubitemid 129640285)
9. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V, 1987. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664-666. (Pubitemid 18005584)
10. Doolan DL, Martinez-Alier N, 2006. Immune response to preerythrocytic stages of malaria parasites. Curr Mol Med 6: 169-185.
11. Mellouk S, Green SJ, Nacy CA, Hoffman SL, 1991. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol 146: 3971-3976.
12. Mellouk S, Maheshwari RK, Rhodes-Feuillette A, Beaudoin RL, Berbiguier N, Matile H, Miltgen F, Landau I, Pied S, Chigot JP, Friedman RM, Mazier D, 1987. Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J Immunol 139: 4192- 4195.
13. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM, Maloy WL, Hoffman SL, Wirtz RA, Schneider I, Woollett GR, Young JF, Hockmeyer WT, 1987. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236: 453-456. (Pubitemid 17071994)
14. Graves P, Gelband H, 2003. Vaccines for preventing malaria. Cochrane Database Syst Rev CD000129.
15. Moorthy V, Smith PG, Kieny MP, 2009. A vaccine against malaria: a substantial step forward. Lancet 373: 1411-1412.
16. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR, 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178: 1139-1144. (Pubitemid 28452210)
17. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927-1934. (Pubitemid 34072872)
18. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420. (Pubitemid 39370716)
19. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitie MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL, 2007. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-1551. (Pubitemid 350018877)
20. Moorthy VS, Reed Z, Smith PG, 2009. Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review. Malar J 8: 23.
21. Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL, 2007. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 12: 37-46. (Pubitemid 44973852)
22. Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, Milman J, Guinovart C, Mandomando I, Lopez-Pua Y, Lievens M, Owusu- Ofori A, Dubois MC, Cahill CP, Koutsoukos M, Sillman M, Thompson R, Dubovsky F, Ballou WR, Cohen J, Alonso PL, 2007. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malariaendemic region of Mozambique: a Phase I/IIb randomized double- blind bridging trial. Trials 8: 11.
23. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ, 2005. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23: 4148-4157. (Pubitemid 40814590)
24. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U, 2003. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171: 6961-6967. (Pubitemid 37532133)
25. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD, Palacios R, Chen-Mok M, Corradin G, Are´valo-Herrera M, 2005. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73: 3-9. (Pubitemid 41688442)
26. Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF, 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 75: 1177-1185. (Pubitemid 46385808)
27. Are´valo-Herrera M, Herrera S, 2001. Plasmodium vivax malaria vaccine development. Mol Immunol 38: 443-455. (Pubitemid 34008474)
28. Are´valo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, Lopez JA, Herrera S, 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539-551. (Pubitemid 28365364)
29. Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, Lopez JA, Corradin G, Are´valo-Herrera M, 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 1535-1546.
30. Are´valo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, Gonzalez JM, Restrepo JC, Lopez JA, Valmori D, Corradin G, Herrera S, 2002. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol 24: 161-169. (Pubitemid 34451226)
31. Atherton E, Logan CJ, Sheppard RC, 1981. Procedures for solidphase synthesis using N-fluorenylmethoxycarbonylamino-acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J Chem Soc, Perkin Trans 1 538-546.
32. Roggero MA, Servis C, Corradin G, 1997. A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry. FEBS Lett 408: 285-288. (Pubitemid 27227016)
33. Bouharoun-Tayoun H, Druilhe P, 1992. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60: 1473-1481.
34. Druilhe P, Tall A, Sokhna C, 2005. Worms can worsen malaria: towards a new means to roll back malaria? Trends Parasitol 21: 359-362. (Pubitemid 40968136)
35. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P, 2000. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620. (Pubitemid 30253834)
36. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P, 2004. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamaterich protein. Infect Immun 72: 247-252. (Pubitemid 38018182)
37. Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Are´valo- Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratorybred Anopheles albimanus. Ann Trop Med Parasitol 91: 49- 60.
38. Gonzalez JM, Hurtado S, Are´valo-Herrera M, Herrera S, 2001. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Mem Inst Oswaldo Cruz 96: 709-712. (Pubitemid 33704179)
39. Renia L, Vigario AM, Belnoue E, 2002. Inhibition of sporozoite invasion. The double-staining assay. Methods Mol Med 72: 507-516.
40. Nasiri H, Forouzandeh M, Rasaee MJ, Rahbarizadeh F, 2005. Modified salting-out method: high-yield, high-quality genomic DNA extraction from whole blood using laundry detergent. J Clin Lab Anal 19: 229-232. (Pubitemid 41740345)
41. Herrera S, De Plata C, Gonzalez M, Perlaza BL, Bettens F, Corradin G, Are´valo-Herrera M, 1997. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol 19: 161- 170.
42. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G, 2009. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27: 328-335.
43. Ying P, Shakibaei M, Patankar MS, Clavijo P, Beavis RC, Clark GF, Frevert U, 1997. The malaria circumsporozoite protein: interaction of the conserved regions I and II-plus with heparin-like oligosaccharides in heparan sulfate. Exp Parasitol 85: 168-182. (Pubitemid 27247977)
44. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P, 2005. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 201: 27-33. (Pubitemid 40130080)
45. Ancsin JB, Kisilevsky R, 2004. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J Biol Chem 279: 21824-21832. (Pubitemid 38679371)
46. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC, 1992. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 60: 1834-1839.
47. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH, 2005. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73: 3587-3597. (Pubitemid 40745903)
48. Druilhe P, Perignon JL, 1994. Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol Lett 41: 115-120. (Pubitemid 24279474)
49. Thomas BE, Manocha M, Haq W, Adak T, Pillai CR, Rao DN, 2001. Modulation of the humoral response to repeat and nonrepeat sequences of the circumsporozoite protein of Plasmodium vivax using novel adjuvant and delivery systems. Ann Trop Med Parasitol 95: 451-472. (Pubitemid 32730481)
50. Fruci D, Rovero P, Falasca G, Chersi A, Sorrentino R, Butler R, Tanigaki N, Tosi R, 1993. Anchor residue motifs of HLA class- I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. Hum Immunol 38: 187-192. (Pubitemid 24018338)
51. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH, 1994. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum Immunol 39: 155-162. (Pubitemid 24151138)
52. Tippawangkosol P, Duangchanda T, Ubalee R, Ruengweerayut R, Hirayama K, Na-Bangchang K, 2009. Identification of HLAA24 restricted pre-erythrocytic stage specific T-cell epitopes using Plasmodium falciparum synthetic peptides: a preliminary study. Southeast Asian J Trop Med Public Health 40: 10-17.